These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12061340)

  • 1. Report on the International Workshop on the Biopharmaceutics Classification System (BCS): scientific and regulatory aspects in practice.
    Kanfer I
    J Pharm Pharm Sci; 2002; 5(1):1-4. PubMed ID: 12061340
    [No Abstract]   [Full Text] [Related]  

  • 2. Scientific considerations concerning the EMA change in the definition of "dose" of the BCS-based biowaiver guideline and implications for bioequivalence.
    Daousani C; Macheras P
    Int J Pharm; 2015 Jan; 478(2):606-9. PubMed ID: 25437115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards.
    Löbenberg R; Amidon GL
    Eur J Pharm Biopharm; 2000 Jul; 50(1):3-12. PubMed ID: 10840189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond.
    Polli JE; Abrahamsson BS; Yu LX; Amidon GL; Baldoni JM; Cook JA; Fackler P; Hartauer K; Johnston G; Krill SL; Lipper RA; Malick WA; Shah VP; Sun D; Winkle HN; Wu Y; Zhang H
    AAPS J; 2008 Jun; 10(2):373-9. PubMed ID: 18679807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
    Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
    J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium.
    Bransford P; Cook J; Gupta M; Haertter S; He H; Ju R; Kanodia J; Lennernäs H; Lindley D; Polli JE; Wenning L; Wu Y
    Mol Pharm; 2020 Feb; 17(2):361-372. PubMed ID: 31846335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol.
    Vogelpoel H; Welink J; Amidon GL; Junginger HE; Midha KK; Möller H; Olling M; Shah VP; Barends DM
    J Pharm Sci; 2004 Aug; 93(8):1945-56. PubMed ID: 15236445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the biopharmaceutical classification system in clinical drug development--an industrial view.
    Cook J; Addicks W; Wu YH
    AAPS J; 2008 Jun; 10(2):306-10. PubMed ID: 18500563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
    Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
    J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
    Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
    Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Biopharmaceutics Classification System-based biowaivers.
    Cook JA; Davit BM; Polli JE
    Mol Pharm; 2010 Oct; 7(5):1539-44. PubMed ID: 20735084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
    Golovenko NIa; Borisiuk IIu
    Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
    Lennernäs H; Abrahamsson B
    J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research.
    Varma MV; Khandavilli S; Ashokraj Y; Jain A; Dhanikula A; Sood A; Thomas NS; Pillai O; Sharma P; Gandhi R; Agrawal S; Nair V; Panchagnula R
    Curr Drug Metab; 2004 Oct; 5(5):375-88. PubMed ID: 15544432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System.
    Bou-Chacra N; Melo KJC; Morales IAC; Stippler ES; Kesisoglou F; Yazdanian M; Löbenberg R
    AAPS J; 2017 Jul; 19(4):989-1001. PubMed ID: 28516359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BCS strategies at drug discovery and development stages].
    Takagi T
    Nihon Yakurigaku Zasshi; 2009 Jul; 134(1):24-7. PubMed ID: 19602783
    [No Abstract]   [Full Text] [Related]  

  • 17. Gordon L. Amidon: Very Sustained Drug Absorption.
    Donovan MD; Polli JE; Langguth P; Tamai I; Vig B; Yu LX
    J Pharm Sci; 2015 Sep; 104(9):2650-63. PubMed ID: 26053319
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.
    Malm-Erjefält M; Ekblom M; Vouis J; Zdravkovic M; Lennernäs H
    Mol Pharm; 2015 Nov; 12(11):4166-73. PubMed ID: 26426736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
    Dokoumetzidis A; Macheras P
    Int J Pharm; 2006 Sep; 321(1-2):1-11. PubMed ID: 16920290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers.
    Parr A; Hidalgo IJ; Bode C; Brown W; Yazdanian M; Gonzalez MA; Sagawa K; Miller K; Jiang W; Stippler ES
    Pharm Res; 2016 Jan; 33(1):167-76. PubMed ID: 26286187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.